A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab 1 significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy. The trial results, published today in The Lancet, are good news for non-small cell lung cancer patients who are not eligible for standard of care platinum-based chemotherapy, due to concerns about their ability to withstand the treatment.

https://www.miragenews.com/immunotherapy-boosts-long-term-survival-in-1042357/

#miragenews